Milestone Pharmaceuticals (MIST)

• Market cap: $98.7M
• 1 day: 0.00%
• 5 days: 1.09%
• 1 month: 0.00%
• 3 months: 20.13%
• 6 months: 33.09%
• Year to date: 2.78%
• 1 year: -7.04%
• 5 years: -88.14%
• 10 years: -87.96%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Employees: 47

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

8% more funds holding

Funds holding: 40 [Q2] → 43 (+3) [Q3]

1% more capital invested

Capital invested by funds: $43.3M [Q2] → $43.6M (+$295K) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

7.67% less ownership

Funds ownership: 61.5% [Q2] → 53.83% (-7.67%) [Q3]

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $25 1,251% upside
• Avg. target: $25 1,251% upside
• High target: $25 1,251% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target

1,251% upside $25

Buy Reiterated

14 Oct 2024